Compare Gap Inc (GAP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Pfizer Inc — how do they compare? Gap Inc trades at $20.88 (market cap $7.30B), while Pfizer Inc trades at $25.27 (market cap $141.46B). The key difference: Pfizer Inc is far larger — about 19.4× Gap Inc's market cap, and Pfizer Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| GAP | PFE | |
|---|---|---|
Market Cap | $7.30B | $141.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $28.56 |
52-Week Low | $18.35 | $23.29 |
Enterprise Value | $10.38B | $192.12B |
Dividend Yield | 3.45% | 6.93% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $20.13, up 1.67% today, with a bullish technical signal but mixed moving averages. The company shows strong profitability with a 6.25% net income margin and 27.58% ROE, supported by positive earnings beats in recent quarters. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B for 2025. Recent news highlights Gap's digital transformation and Athleta brand turnaround efforts, though legal investigations present headwinds.
The stock appears undervalued with a P/E of 8.05 and consensus price target of $27.00, implying 34% upside. Key opportunities include earnings growth and margin expansion, but risks involve competitive pressures and ongoing legal probes. Analyst sentiment is mixed with 39.58% buy ratings, suggesting cautious optimism for value-oriented investors.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
